Trigeminal neuralgia causes excruciating, lancinating facial pain that severely impairs patient quality of life. Although medical therapy remains the first-line choice, many patients experience pharmacoresistance or intolerable drug toxicities. Consequently, interventional practitioners frequently consider percutaneous ablative procedures to relieve debilitating symptoms. Among these approaches, percutaneous balloon compression provides an established, minimally invasive technique for targeting the Gasserian ganglion. Recently, clinical researchers investigated whether combining mechanical compression with local anti-inflammatory agents could prolong pain relief. Specifically, a multicenter study evaluated percutaneous balloon compression plus perineural methylprednisolone in refractory classical trigeminal neuralgia. This analysis reviews the clinical findings, durability, and safety outcomes over twelve months.

Evaluating Percutaneous Balloon Compression and Adjunctive Steroids

Managing pharmacoresistant trigeminal neuralgia represents a difficult therapeutic challenge for neurologists and neurosurgeons. First-line anticonvulsants, including carbamazepine and oxcarbazepine, often induce severe cognitive or hepatic adverse effects. When pharmacological measures fail, percutaneous techniques provide attractive alternatives to open microvascular decompression. In particular, percutaneous balloon compression selectively injures large myelinated A-beta fibers responsible for triggering sharp paroxysmal pain. However, mechanical compression inherently provokes localized inflammation, tissue ischemia, and acute perineural edema. Therefore, clinicians hypothesized that immediate injection of a depot corticosteroid might alleviate this mechanical trauma. Perineural methylprednisolone acetate theoretically stabilizes injured axonal membranes and reduces ectopic nociceptive discharge. Consequently, researchers designed a multicenter retrospective series to evaluate this combined interventional strategy. The study reviewed fifty consecutive adult patients presenting with refractory classical unilateral trigeminal neuralgia treated between 2020 and 2025. By analyzing longitudinal pain scores and recurrence rates, this investigation clarifies the real-world value of adding local steroids to mechanical rhizotomy. This observational cohort offers relevant clinical benchmarks for interventional pain practitioners.

Surgical Technique and Perineural Steroid Protocol

The interventional protocol utilized standard surgical landmarks to achieve safe percutaneous cannulation. Operating neurosurgeons executed Hartel's trans-oval approach under biplanar fluoroscopic guidance in all fifty cases. After successfully entering the foramen ovale, clinicians positioned a balloon catheter within Meckel's cave. The operators then inflated the balloon with non-ionic contrast until obtaining the classic pear-shaped profile. Furthermore, surgeons sustained compression for sixty to one hundred and twenty seconds to ensure adequate mechanical gangliolysis. Immediately following deflation, clinicians administered twenty to forty milligrams of perineural methylprednisolone acetate directly into the ganglion pocket. This local steroid application aimed to attenuate acute tissue edema generated during mechanical compression. Additionally, patients attended scheduled follow-up assessments at one week, one month, six months, and twelve months postoperatively. Evaluators recorded pain severity using the Barrow Neurological Institute scale alongside visual analogue scale assessments. This structured evaluation provided clear longitudinal data regarding immediate relief and long-term symptom control. In addition, assessing categorical visual scores helped determine overall functional recovery.

Analgesic Outcomes and Recurrence Over 12 Months

The observed pain outcomes demonstrated rapid initial relief followed by substantial attenuation over twelve months. At one week, sixty percent of patients achieved excellent pain control, reaching Barrow Neurological Institute Class I or II. Similarly, fifty-six percent sustained this high level of relief at the one-month checkpoint. Visual analogue scale scores dropped dramatically from a baseline mean of 9.0 ± 0.6 to 2.5 ± 1.2 at one week. Moreover, reductions in pain scores remained statistically significant at all subsequent follow-up intervals compared to baseline values. Nevertheless, clinical durability diminished markedly over time. By six months, the proportion of individuals maintaining Class I or II pain relief decreased to thirty-four percent. At twelve months, only thirty-two percent maintained adequate pain relief without daily medication. In total, thirty-one of forty-five followed patients met the formal criteria for pain recurrence by twelve months. Thus, nearly sixty-nine percent of individuals failed to maintain durable pain control over twelve months.

Safety Profile and Post-Procedural Complications

Regarding procedural safety, the combined approach demonstrated an acceptable adverse event profile without life-threatening complications. Importantly, no patient experienced severe events such as intracranial hemorrhage, arterial injury, corneal keratitis, or central nervous system infection. Instead, recorded complications were predominantly sensory and motor sequelae related to mechanical nerve compression. Mild facial hypoesthesia developed in forty-four percent of participants, representing the most common postoperative complaint. This sensory blunting typically reflects intentional mechanical disruption of myelinated sensory fibers within the trigeminal ganglion. In addition, twenty percent of treated patients experienced transient masticatory muscle weakness due to temporary motor root neuropraxia. Crucially, these motor deficits resolved spontaneously during clinical follow-up without causing permanent functional disability. Furthermore, no patients developed anesthesia dolorosa, a dreaded complication characterized by intractable deafferentation dysesthesias. Therefore, adjunctive methylprednisolone did not amplify procedural morbidity beyond expected neurosurgical rates. Clinicians must nevertheless educate patients regarding the high likelihood of transient postoperative numbness.

Clinical Implications and Future Research Directions

These study findings offer important practical implications for neurosurgeons and pain specialists managing facial pain syndromes. In Indian clinical practice, percutaneous techniques remain widely utilized due to lower procedural costs and feasibility in elderly cohorts. However, practitioners must communicate realistic expectations regarding long-term durability. Although perineural steroids offer plausible biological benefits against acute inflammation, this single-arm study cannot confirm incremental efficacy. Because historical compression studies report variable recurrence rates, the sixty-nine percent recurrence observed here suggests steroids do not extend remission. In addition, the lack of a comparator group limits definitive clinical conclusions. Consequently, researchers must regard these observational findings as hypothesis-generating. Future research should prioritize multicenter, randomized controlled trials directly comparing balloon compression with adjunctive steroids against compression alone. Furthermore, investigating modified compression durations and alternative pharmacologic agents may help optimize interventional durability for refractory trigeminal neuralgia. Ultimately, rigorous comparative studies will define the true therapeutic merit of adjunctive perineural steroids.

Frequently Asked Questions

How does percutaneous balloon compression relieve trigeminal neuralgia?

Percutaneous balloon compression works by applying mechanical pressure directly to the Gasserian ganglion within Meckel's cave. This controlled compression selectively damages large myelinated A-beta nerve fibers responsible for triggering paroxysmal facial pain. By interrupting these abnormal sensory circuits, the procedure rapidly halts excruciating pain episodes in medically refractory patients.

Why did pain relief diminish over twelve months of follow-up?

Although methylprednisolone transiently suppresses mechanical inflammation and perineural edema, its biological activity is self-limiting. As the depot steroid metabolizes over subsequent weeks, underlying neuropathic mechanisms and peripheral nerve regeneration can re-establish nociceptive transmission. Consequently, adjunctive corticosteroids failed to prevent late recurrence or sustain long-term pain-free survival beyond initial months.

What adverse effects are most common following balloon compression?

The most frequent adverse events are mild ipsilateral facial hypoesthesia and transient masticatory muscle weakness. Facial numbness occurs in nearly half of patients due to mechanical sensory nerve injury, whereas jaw weakness results from temporary motor root neuropraxia. Fortunately, motor weakness resolves spontaneously within weeks to months without intervention.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Soliman AY et al. Percutaneous balloon compression followed by perineural methylprednisolone for trigeminal neuralgia: A 50-patient retrospective series with 12-month outcomes. Clin Neurol Neurosurg. 2026 Oct. doi: 10.1016/j.clineuro.2026.109537. PMID: 42284923.
2. Bergenheim AT, Asplund P, Linderoth B. Percutaneous balloon compression for trigeminal neuralgia: review of surgical techniques and clinical outcomes. World Neurosurg. 2013;79(6):e11-e17. doi:10.1016/j.wneu.2012.03.024.
3. Bick SKB, Eskandar EN. Surgical treatment of trigeminal neuralgia. Neurotherapeutics. 2017;14(3):697-712. doi:10.1007/s13311-017-0544-x.